Skip to main content

Dr. Rachna Shroff, MD

Hematology & Oncology (Hematology & Oncology Physician)

3838 N Campbell Ave Unit 10
Tucson, AZ 85719

Who else practices at this address →

Pima County includes primary care (34% of residents) and dental (4% of residents) and mental health (14% of residents) shortage areas. About shortage areas

Call (314) 853-1185

  • Medicare participating

At a glance

Years since graduation
22
In the NPI registry since
2007
Medicare patients seen, 2024
105

Licensed in Texas since 2007, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2004Medical school: Jefferson Medical College of Thomas Jefferson University
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    TX license M7626 (first issued 2007; canc non-renewal)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
105
Services billed
295
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes16272
Established patient office or other outpatient visit, 30-39 minutes2823
New patient office or other outpatient visit, 60-74 minutes1616

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 10 companies reported 26 payments worth $21,046 in total to this clinician.

By type
Consulting Fee$9,805
Compensation for services other than consulting (speaking, faculty)$6,370
Travel and Lodging$1,952
Grant$1,800
Food and Beverage$1,118

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
May 9, 2025Ipsen Biopharmaceuticals, Inc
May 9, 2025
Compensation for services other than consulting (speaking, faculty)
Onivyde; Tazverik · Oncology
$6,370
Jan 27, 2025AstraZeneca Pharmaceuticals LP
Jan 27, 2025
Consulting Fee
IMFINZI · Oncology
Company’s descriptionResearch Related Service
$5,740
Jan 23, 2025AstraZeneca Pharmaceuticals LP
Jan 23, 2025
Grant
Company’s descriptionOther Support
$1,800
May 9, 2025AstraZeneca Pharmaceuticals LP
May 9, 2025
Consulting Fee
IMFINZI · Oncology
$1,640
Nov 14, 2025AstraZeneca UK Limited
Nov 14, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$1,230
Nov 5, 2025AstraZeneca Pharmaceuticals LP
Nov 5, 2025
Consulting Fee$820
May 9, 2025Ipsen Biopharmaceuticals, Inc
May 9, 2025
Travel and Lodging
Onivyde; Tazverik · Oncology · travel to Dallas, TX · in-kind
$726
Feb 7, 2025AstraZeneca Pharmaceuticals LP
Feb 7, 2025
Travel and Lodging
IMFINZI · Oncology · travel to San Francisco, CA
Company’s descriptionResearch Related Service
$429
Jul 31, 2025Boston Scientific Corporation
Jul 31, 2025
Consulting Fee
TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) · TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)_PI
$375
Nov 8, 2025Novocure Inc.
Nov 8, 2025
Travel and Lodging
travel to Dallas, TX
$368
All 12 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Nov 14, 2025AstraZeneca UK Limited
Nov 14, 2025
Consulting Fee
Company’s descriptionResearch Related Service
$1,230
Nov 8, 2025Novocure Inc.
Nov 8, 2025
Travel and Lodging
travel to Dallas, TX
$368
Nov 5, 2025AstraZeneca Pharmaceuticals LP
Nov 5, 2025
Consulting Fee$820
Jul 31, 2025Boston Scientific Corporation
Jul 31, 2025
Consulting Fee
TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) · TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)_PI
$375
May 9, 2025Ipsen Biopharmaceuticals, Inc
May 9, 2025
Compensation for services other than consulting (speaking, faculty)
Onivyde; Tazverik · Oncology
$6,370
May 9, 2025AstraZeneca Pharmaceuticals LP
May 9, 2025
Consulting Fee
IMFINZI · Oncology
$1,640
May 9, 2025Ipsen Biopharmaceuticals, Inc
May 9, 2025
Travel and Lodging
Onivyde; Tazverik · Oncology · travel to Dallas, TX · in-kind
$726
May 9, 2025Ipsen Biopharmaceuticals, Inc
May 9, 2025
Travel and Lodging
Onivyde; Tazverik · Oncology · travel to Dallas, TX · in-kind
$344
Feb 7, 2025AstraZeneca Pharmaceuticals LP
Feb 7, 2025
Travel and Lodging
IMFINZI · Oncology · travel to San Francisco, CA
Company’s descriptionResearch Related Service
$429
Feb 7, 2025AstraZeneca Pharmaceuticals LP
Feb 7, 2025
Travel and Lodging
IMFINZI · Oncology · travel to San Francisco, CA
Company’s descriptionResearch Related Service
$86.91
Jan 27, 2025AstraZeneca Pharmaceuticals LP
Jan 27, 2025
Consulting Fee
IMFINZI · Oncology
Company’s descriptionResearch Related Service
$5,740
Jan 23, 2025AstraZeneca Pharmaceuticals LP
Jan 23, 2025
Grant
Company’s descriptionOther Support
$1,800

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Arizona →

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 9 companies. The companies reported $128,087 in research payments for these studies, mostly to the institutions running them.

  • A phase 2 basket study of tucatinib in combination with trastuzumab in subjects with previously treated locallyadvanced unresectable or metastatic solid tumors driven by HER2 alterations
    Pfizer Inc.
  • EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
    Novocure Inc.
  • A phase III randomized control trial of gemcitbaine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers
    Celgene Corporation
  • Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
    Eli Lilly and Company · Active, not recruiting · NCT04521686
  • A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response …
    Merck Sharp & Dohme LLC
  • Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer
    Exelixis Inc.
  • Brightline-2 PhIIa/IIb Brigimadlin mono in MDM2 amp tumors
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • Study name not reported
    Organon Llc
  • SRF388-201
    Coherus Oncology, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Tucson

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 18, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1942425350. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.